Nephrotic syndrome in kids can mean frequent relapses, high steroid burden, and tough treatment choices. So which helps maintain remission better: Tacrolimus or MMF?
See the Visual Abstract Krithika Mohan
This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?
Summary of the STEPS trial which will be a twitter spaces discussion
This week, we will discuss the HIT trial- a large randomized study challenging one of the most reflexive responses in hospital medicine: see hyponatremia, fix the sodium. But what if correcting the number doesn’t change what actually matters?
Nephrotic syndrome in kids can mean frequent relapses, high steroid burden, and tough treatment choices. So which helps maintain remission better: Tacrolimus or MMF?
See the Visual Abstract Krithika Mohan
El ensayo STAMP comparó ambos tratamientos en niños con recaídas frecuentes o corticodependencia.
¿Cuál fue más eficaz? ¿Qué tan seguros son?
🖼️ Revisa el VA completo #NephJC
Nephrotic syndrome in children, especially those with frequent relapses or steroid dependence, remains a therapeutic challenge. The STAMP trial compared tacrolimus and mycophenolate mofetil to help guide treatment decisions.